{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:28:48Z","timestamp":1786786128291,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07070-5","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T12:54:02Z","timestamp":1779540842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic model for diffuse large B-cell lymphoma based on an HBV-associated gene signature and immune microenvironment insights"],"prefix":"10.1007","volume":"105","author":[{"given":"Guanhua","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"5","key":"7070_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"issue":"1","key":"7070_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Jon EA (2022) Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk Lymphoma 63(1):54\u201363. https:\/\/doi.org\/10.1080\/10428194.2021.1975188","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"7070_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ et al (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378(15):1396\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"issue":"20","key":"7070_CR4","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1182\/blood.2022018248","volume":"141","author":"W Alduaij","year":"2023","unstructured":"Alduaij W, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M et al (2023) Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood 141(20):2493\u20132507. https:\/\/doi.org\/10.1182\/blood.2022018248","journal-title":"Blood"},{"key":"7070_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-57362-1_1","volume":"217","author":"JT Schiller","year":"2021","unstructured":"Schiller JT, Lowy DR (2021) An Introduction to Virus Infections and Human Cancer. Recent Results Cancer Res 217:1\u201311. https:\/\/doi.org\/10.1007\/978-3-030-57362-1_1","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"7070_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2011.09017.x","volume":"156","author":"JB Harford","year":"2012","unstructured":"Harford JB (2012) Viral infections and human cancers: the legacy of Denis Burkitt. Br J Haematol 156(6):709\u2013718. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.09017.x","journal-title":"Br J Haematol"},{"issue":"6","key":"7070_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","volume":"13","author":"C de Martel","year":"2012","unstructured":"de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13(6):607\u2013615. https:\/\/doi.org\/10.1016\/S1470-2045(12)70137-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"7070_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","volume":"22","author":"M Iannacone","year":"2022","unstructured":"Iannacone M, Guidotti LG (2022) Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol 22(1):19\u201332. https:\/\/doi.org\/10.1038\/s41577-021-00549-4","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"7070_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s12885-019-5718-x","volume":"19","author":"X Zhou","year":"2019","unstructured":"Zhou X, Pan H, Yang P, Ye P, Cao H, Zhou H (2019) Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma. BMC Cancer 19(1):477. https:\/\/doi.org\/10.1186\/s12885-019-5718-x","journal-title":"BMC Cancer"},{"key":"7070_CR10","doi-asserted-by":"publisher","first-page":"1275800","DOI":"10.3389\/fonc.2023.1275800","volume":"13","author":"M Rosenberg","year":"2023","unstructured":"Rosenberg M, Poluch M, Thomas C, Sindaco P, Khoo A, Porcu P (2023) Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities. Front Oncol 13:1275800. https:\/\/doi.org\/10.3389\/fonc.2023.1275800","journal-title":"Front Oncol"},{"key":"7070_CR11","doi-asserted-by":"publisher","first-page":"1216610","DOI":"10.3389\/fimmu.2023.1216610","volume":"14","author":"X Wan","year":"2023","unstructured":"Wan X, Young KH, Bai O (2023) HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy. Front Immunol 14:1216610. https:\/\/doi.org\/10.3389\/fimmu.2023.1216610","journal-title":"Front Immunol"},{"issue":"4","key":"7070_CR12","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3748\/wjg.v22.i4.1497","volume":"22","author":"CH Sukowati","year":"2016","unstructured":"Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C (2016) Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol 22(4):1497\u20131512. https:\/\/doi.org\/10.3748\/wjg.v22.i4.1497","journal-title":"World J Gastroenterol"},{"issue":"1","key":"7070_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000347209","volume":"31","author":"M Ringelhan","year":"2013","unstructured":"Ringelhan M, Heikenwalder M, Protzer U (2013) Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development. Dig Dis 31(1):138\u2013151. https:\/\/doi.org\/10.1159\/000347209","journal-title":"Dig Dis"},{"issue":"3","key":"7070_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"issue":"11","key":"7070_CR15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423\u20131437. https:\/\/doi.org\/10.1038\/nm.3394","journal-title":"Nat Med"},{"issue":"10","key":"7070_CR16","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY et al (2021) The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell 39(10):1422\u20131437. e10","journal-title":"Cancer Cell"},{"issue":"12","key":"7070_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood.2023021002","volume":"143","author":"L Cerchietti","year":"2024","unstructured":"Cerchietti L (2024) Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma. Blood 143(12):1101\u20131111. https:\/\/doi.org\/10.1182\/blood.2023021002","journal-title":"Blood"},{"issue":"Suppl 1","key":"7070_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer D, Brentjens R (2019) CAR T-cell therapy: Full speed ahead. Hematol Oncol 37(Suppl 1):95\u2013100. https:\/\/doi.org\/10.1002\/hon.2591","journal-title":"Hematol Oncol"},{"issue":"8","key":"7070_CR19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/jvh.12892","volume":"25","author":"M Li","year":"2018","unstructured":"Li M, Gan Y, Fan C, Yuan H, Zhang X, Shen Y et al (2018) Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies. J Viral Hepat 25(8):894\u2013903. https:\/\/doi.org\/10.1111\/jvh.12892","journal-title":"J Viral Hepat"},{"issue":"3","key":"7070_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.03.022","volume":"28","author":"YT Zhang","year":"2020","unstructured":"Zhang YT, Feng D, Wang Y, Li DP, Li ZY, Qiu TT et al (2020) [Expression and Clinical Significance of EZH2 in Patients with Diffuse Large B Cell Lymphoma Accompanied by HBV Infection]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 28(3):855\u2013860. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2020.03.022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"7070_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1743-422X-11-54","volume":"11","author":"TT Hu","year":"2014","unstructured":"Hu TT, Song XF, Lei Y, Hu HD, Ren H, Hu P (2014) Expansion of circulating TFH cells and their associated molecules: involvement in the immune landscape in patients with chronic HBV infection. Virol J 11:54. https:\/\/doi.org\/10.1186\/1743-422X-11-54","journal-title":"Virol J"},{"issue":"12","key":"7070_CR22","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1097\/PAS.0000000000001577","volume":"44","author":"J Zhang","year":"2020","unstructured":"Zhang J, Weng Z, Huang Y, Li M, Wang F, Wang Y et al (2020) High-grade B-Cell Lymphoma With MYC, BCL2, and\/or BCL6 Translocations\/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China. Am J Surg Pathol 44(12):1602\u20131611. https:\/\/doi.org\/10.1097\/PAS.0000000000001577","journal-title":"Am J Surg Pathol"},{"issue":"28","key":"7070_CR23","doi-asserted-by":"publisher","first-page":"25061","DOI":"10.18632\/oncotarget.4677","volume":"6","author":"L Deng","year":"2015","unstructured":"Deng L, Song Y, Young KH, Hu S, Ding N, Song W et al (2015) Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget 6(28):25061\u201325073. https:\/\/doi.org\/10.18632\/oncotarget.4677","journal-title":"Oncotarget"},{"issue":"7","key":"7070_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/annonc\/mdx128","volume":"28","author":"A Kuhnl","year":"2017","unstructured":"Kuhnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P et al (2017) Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol 28(7):1540\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdx128","journal-title":"Ann Oncol"},{"issue":"19","key":"7070_CR25","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1182\/blood-2012-09-455865","volume":"120","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C (2012) TP53 mutations and rituximab-CHOP. Blood 120(19):3867\u20133869. https:\/\/doi.org\/10.1182\/blood-2012-09-455865","journal-title":"Blood"},{"issue":"6","key":"7070_CR26","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3892\/ijo.2011.1170","volume":"39","author":"L Stefancikova","year":"2011","unstructured":"Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B et al (2011) Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Int J Oncol 39(6):1413\u20131420. https:\/\/doi.org\/10.3892\/ijo.2011.1170","journal-title":"Int J Oncol"},{"issue":"9","key":"7070_CR27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2020008376","volume":"140","author":"KJ Savage","year":"2022","unstructured":"Savage KJ (2022) Primary mediastinal large B-cell lymphoma. Blood 140(9):955\u2013970. https:\/\/doi.org\/10.1182\/blood.2020008376","journal-title":"Blood"},{"issue":"31","key":"7070_CR28","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.2174\/092986710793213724","volume":"17","author":"O Zitka","year":"2010","unstructured":"Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M et al (2010) Matrix metalloproteinases. Curr Med Chem 17(31):3751\u20133768. https:\/\/doi.org\/10.2174\/092986710793213724","journal-title":"Curr Med Chem"},{"issue":"1","key":"7070_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jped.2022.05.004","volume":"99","author":"BO Silva","year":"2023","unstructured":"Silva BO, Medeiros JW, Albuquerque GS, Valderrama PM, Barbosa AHQ, de Souza JM et al (2023) Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin\u2019s lymphoma patients. J Pediatr (Rio J) 99(1):59\u201364. https:\/\/doi.org\/10.1016\/j.jped.2022.05.004","journal-title":"J Pediatr (Rio J)"},{"key":"7070_CR30","doi-asserted-by":"publisher","unstructured":"Serra R (2020) Matrix Metalloproteinases in Health and Disease. Biomolecules 10(8). https:\/\/doi.org\/10.3390\/biom10081138","DOI":"10.3390\/biom10081138"},{"key":"7070_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.semcancer.2017.11.008","volume":"56","author":"A Alaseem","year":"2019","unstructured":"Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A, Rathinavelu A (2019) Matrix Metalloproteinases: A challenging paradigm of cancer management. Semin Cancer Biol 56:100\u2013115. https:\/\/doi.org\/10.1016\/j.semcancer.2017.11.008","journal-title":"Semin Cancer Biol"},{"issue":"14","key":"7070_CR32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329(14):987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"issue":"1","key":"7070_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41408-023-00930-7","volume":"13","author":"J Jelicic","year":"2023","unstructured":"Jelicic J, Juul-Jensen K, Bukumiric Z, Roost Clausen M, Ludvigsen Al-Mashhadi A, Pedersen RS et al (2023) Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer J 13(1):157. https:\/\/doi.org\/10.1038\/s41408-023-00930-7","journal-title":"Blood Cancer J"},{"issue":"23","key":"7070_CR34","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V et al (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 135(23):2041\u20132048. https:\/\/doi.org\/10.1182\/blood.2019002729","journal-title":"Blood"},{"issue":"6","key":"7070_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A et al (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837\u2013842. https:\/\/doi.org\/10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"issue":"22","key":"7070_CR36","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1182\/bloodadvances.2024013699","volume":"8","author":"S Kim","year":"2024","unstructured":"Kim S, Jeong H, Ahn HK, Han B, Lee KC, Song YK et al (2024) Increased CCL2\/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC\/BCL2 double-expressor DLBCL. Blood Adv 8(22):5773\u20135788. https:\/\/doi.org\/10.1182\/bloodadvances.2024013699","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07070-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:25Z","timestamp":1786785625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07070-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7070"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07070-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"335"}}